Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx, GeneCell Ink Pact to Offer HPV Test in India

NEW YORK (GenomeWeb News) – IncellDx today said it has reached a deal to offer its molecular diagnostic test for human papillomavirus in India.

Under the terms of the deal, New Delhi-based GeneCell Diagnostics will offer IncellDx's test for detecting oncogenic HPV E6, E7 mRNA through its laboratory partner CureHealth Diagnostics, which will be the first reference lab in India to offer the test.

IncellDx's technology uses a flow cytometry-based method to detect and quantify the expression of viral oncogenes that trigger progression to cervical cancer, providing higher specificity than other tests, according to the Menlo Park, Calif.-based firm.

"The high level of specificity our technology produces has a significant positive economic impact on healthcare delivery costs by potentially reducing the number of unnecessary colposcopy/biopsies," IncellDx Founder and CEO Bruce Patterson said in a statement.

Financial and other terms of the deal were not disclosed.

Earlier this month, IncellDx and Kindstar Global reached a deal to bring the HPV test to China.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.